Table 2 Clinical characteristics of the high- and low-NPS groups before and after propensity score matching
Before matching | After matching | ||||||||
|---|---|---|---|---|---|---|---|---|---|
Low NPS | High NPS | Low NPS | High NPS | ||||||
Characteristics | (N = 400) | (N = 133) | p value | SD | (N = 123) | (N = 123) | p value | SD | |
Age | (years, IQR) | 68 (62 − 75) | 74 (68 − 80) | < 0.001 | 0.476 | 74 (70 − 79) | 73 (67 − 80) | 0.627 | 0.062 |
< 68 | 186 (85.3%) | 32 (14.7%) | < 0.001 | 0.483 | 24 (42.9%) | 32 (57.1%) | 0.287 | 0.156 | |
≥ 68 | 214 (67.9%) | 101 (32.1%) | 99 (52.1%) | 91 (47.9%) | |||||
Sex | Male | 224 (71.6%) | 89 (28.4%) | 0.033 | 0.226 | 75 (48.4%) | 80 (51.6%) | 0.597 | 0.084 |
Female | 176 (80.0%) | 44 (20.0%) | 48 (52.7%) | 43 (47.3%) | |||||
BMI | (kg/m2, IQR) | 22.5 (20.5 − 24.8) | 22.1 (19.7 − 24.0) | 0.047 | 0.2 | 22.4 (19.9 − 24.2) | 22.1 (19.9 − 24.3) | 0.945 | 0.009 |
< 18 | 34 (66.7%) | 17 (33.3%) | 0.069 | 0.235 | 13 (48.1%) | 14 (51.9%) | 1 | 0.026 | |
≥ 18, < 25 | 273 (74.0%) | 96 (26.0%) | 90 (50.3%) | 89 (49.7%) | |||||
≥ 25 | 93 (82.3%) | 20 (17.7%) | 20 (50.0%) | 20 (50.0%) | |||||
CCI | 0 | 207 (83.8%) | 40 (16.2%) | < 0.001 | 0.452 | 39 (50.6%) | 38 (49.4%) | 1 | 0.018 |
≥ 1 | 193 (67.5%) | 93 (32.5%) | 84 (49.7%) | 85 (50.3%) | |||||
ASA-PS | < 3 | 356 (77.7%) | 102 (22.3%) | 0.001 | 0.331 | 102 (52.3%) | 93 (47.7%) | 0.208 | 0.181 |
≥ 3 | 44 (58.7%) | 31 (41.3%) | 21 (41.2%) | 30 (58.8%) | |||||
Tumor location | Colon | 225 (71.4%) | 90 (28.6%) | 0.025 | 0.237 | 81 (49.4%) | 83 (50.6%) | 0.892 | 0.034 |
Rectum | 175 (80.3%) | 43 (19.7%) | 42 (51.2%) | 40 (48.8%) | |||||
Histological type | Differentiated | 389 (76.1%) | 122 (23.9%) | 0.008 | 0.257 | 117 (50.4%) | 115 (49.6%) | 0.784 | 0.07 |
Undifferentiated | 10 (47.6%) | 11 (52.4%) | 6 (42.9%) | 8 (56.1%) | |||||
T stage | T1 | 132 (85.7%) | 22 (14.3%) | < 0.001 | 0.471 | 21 (48.8%) | 22 (51.2%) | 0.911 | 0.097 |
T2 | 69 (79.3%) | 18 (20.7%) | 22 (55.0%) | 18 (45.0%) | |||||
T3 | 161 (70.6%) | 67 (29.4%) | 57 (48.3%) | 61 (51.7%) | |||||
T4 | 38 (59.3%) | 26 (40.7%) | 23 (51.1%) | 22 (48.9%) | |||||
N stage | N0 | 298 (76.8%) | 90 (23.2%) | 0.285 | 0.151 | 89 (51.1%) | 85 (48.9%) | 0.858 | 0.072 |
N1 | 76 (70.4%) | 32 (29.6%) | 27 (47.4%) | 30 (52.6%) | |||||
N2 | 26 (70.3%) | 11 (29.7%) | 7 (46.7%) | 8 (53.3%) | |||||
TNM stage | I | 177 (83.1%) | 36 (16.9%) | 0.002 | 0.365 | 42 (53.8%) | 36 (46.2%) | 0.696 | 0.109 |
II | 121 (69.1%) | 54 (30.9%) | 47 (49.0%) | 49 (51.0%) | |||||
III | 102 (70.3%) | 43 (29.7%) | 34 (47.2%) | 38 (52.8%) | |||||
Surgical approach | Laparoscopy | 306 (77.7%) | 88 (22.3%) | 0.023 | 0.23 | 90 (52.6%) | 81 (47.4%) | 0.268 | 0.159 |
Open surgery | 94 (67.6%) | 45 (32.4%) | 33 (44.0%) | 42 (56.0%) | |||||